The rate of gastric emptying and the incretin, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), response to a meal are known to be major determinants of postprandial blood glucose excursions ([@B1],[@B2]). One strategy to minimize postprandial glycemia could be to administer a small load of protein or fat before a meal, so that the presence of nutrients in the small intestine induces the release of peptides such as GLP-1, GIP, and cholecystokinin (CCK) to slow gastric emptying and stimulate insulin secretion in advance of the main nutrient load ([@B3],[@B4]). We hypothesized that a protein preload would reduce the postprandial glycemic excursion in type 2 diabetic patients by these mechanisms.

RESEARCH DESIGN AND METHODS
===========================

The protocol included eight diet-controlled type 2 diabetic patients (seven male, mean ± SE age 58 ± 3 years, BMI 28.6 ± 1.3 kg/m^2^, duration of known diabetes 5.4 ± 1.1 years, and A1C 6.5 ± 0.2%) who attended the laboratory after an overnight fast (14 h for solids and 12 h for liquids) on three separate occasions. Each patient consumed beef-flavored soup (3.8 g noncaloric beef flavoring dissolved in 350 ml water) 30 min before a mashed potato meal containing 65 g powdered potato (Deb Instant Mashed Potato, Epping, Australia) with 20 g glucose (total: 59.1 g carbohydrate, 4.3 g fat, 5.2 g protein; 1,276.5 kJ), labeled with 20 MBq 99mTc-sulfur colloid ([@B4]). On one day, 55 g whey protein (876.7 kJ) was added to the soup. On another day, 55 g whey was mixed into the potato meal. On a third day, neither the preload nor the meal contained whey. Blood was sampled frequently for blood glucose and plasma hormone measurements.

Measurements
------------

Gastric emptying was assessed by scintigraphy. Data were corrected for radionuclide decay, subject movement, and γ-ray attenuation, and the gastric half-emptying time (T50) was calculated ([@B4]).

Blood glucose concentrations were measured using a glucometer (Medisense Precision QID; Abbott Laboratories, Bedford, MA), which we have validated against the hexokinase technique ([@B5]). Plasma insulin was measured by enzyme-linked immunosorbent assay (ELISA; Diagnostic Systems Laboratories, Webster, TX). Total GLP-1 (GLPIT-36HK; Linco Research, St. Charles, MO), total GIP, and CCK-8 were measured by radioimmunoassay ([@B6]).

Cardiovascular autonomic function was assessed by the variation in R-R interval during deep breathing and the systolic blood pressure changes in response to standing ([@B7]).

Data were evaluated using repeated-measures ANOVA with treatment and time as factors (StatView 5.0; Abacus Concepts, Berkeley, CA). Data are shown as means ± SE; *P* \< 0.05 was considered significant.

RESULTS
=======

Two of the eight subjects had definite autonomic dysfunction. The study was well tolerated.

On the no whey and whey in meal days, emptying was rapid initially and subsequently slower, whereas emptying after the whey preload approximated a linear pattern. Gastric emptying was slowest on the whey preload day (T50: 87.3 ± 5.4 min; *P* = 0.0001) and was slower with whey in the meal (53.0 ± 8.3 min; *P* \< 0.01) than with no whey (39.0 ± 6.2 min).

There were no differences in baseline blood glucose, plasma insulin, GLP-1, GIP, or CCK concentrations ([Fig. 1](#F1){ref-type="fig"}). The incremental area under the curve (iAUC) for blood glucose was less after the whey preload (363.7 ± 64.5 mmol · min^−1^ · l^−1^) and whey in meal (406.3 ± 85.9 mmol · min^−1^ · l^−1^) compared with no whey (734.9 ± 98.9 mmol · min^−1^ · l^−1^; *P* \< 0.005 for both). The iAUCs for insulin, GLP-1, GIP, and CCK were greater when whey was given as a preload (*P* \< 0.05 for all) or in the meal (*P* \< 0.005 for all) compared with no whey. Despite an earlier response, the iAUC for insulin did not differ between whey preload and whey in meal (*P* = 0.50). GLP-1 was greater between −15 min and 90 min with the whey preload compared with whey in meal (*P* = 0.0001), but the overall iAUC did not differ significantly.

![Gastric emptying (*A*), concentrations of blood glucose (*B*), plasma insulin (*C*), plasma GLP-1 (*D*), plasma GIP (*E*), and plasma CCK (*F*) in response to a mashed potato meal in eight type 2 diabetic patients. On each study day, subjects ingested 350 ml beef-flavored soup 30 min before a radiolabeled mashed potato meal; 55 g whey protein was added either to the soup (whey preload) or to the potato (whey in meal) or no whey was given (no whey). Data are means ± SE. \**P* \< 0.05, whey preload vs. whey in meal; \#*P* \< 0.05, whey in meal vs. no whey; §*P* \< 0.05, whey preload vs. no whey.](zdc0090977390001){#F1}

CONCLUSIONS
===========

We demonstrated that whey protein, when given before or with a high-carbohydrate meal, resulted in a substantial reduction in postprandial glycemia in diet-controlled type 2 diabetic patients. Given that the magnitude of the reduction was comparable with what would be hoped for using pharmacological therapy, such as sulfonylureas, these data have considerable implications for nutritional strategies in the management of diabetes.

The pivotal role of the gastrointestinal tract in determining postprandial glycemia has often been overlooked, but it is assuming increasing prominence, partly because of the development of gut peptide--based therapies for diabetes, such as the GLP-1 analog exenatide ([@B8]) and the amylin analog pramlintide ([@B9]), which may act predominantly by slowing gastric emptying. Similar to what we reported after an oil preload ([@B4]), whey slowed gastric emptying substantially, in particular when given before the meal, and is associated with the stimulation of GLP-1 and CCK. However, in contrast to the delayed insulin response observed after oil, whey augmented insulin secretion markedly, possibly by a combination of the incretin effect and the direct stimulation of the β-cells by absorbed amino acids ([@B10]). It is likely that the stimulation of insulin by whey was responsible for the much greater reduction in glycemia after whey than after oil, given that the effects on gastric emptying were comparable.

Although our study involved a small number of subjects who had well-controlled, predominantly uncomplicated type 2 diabetes, the improvement in postprandial glycemia was marked and highly consistent. Further evaluation is now required in poorly controlled patients and those taking oral hypoglycemic agents in order to determine whether the acute effects are sustained in the longer term. It would also be important to confirm whether the effects are evident with a smaller load of protein in order to minimize additional energy intake. Although concerns have been raised about hyperinsulinemia as a risk factor for vascular disease ([@B11]), it is more likely that it represents a marker for other risk factors ([@B12]), and in the UK Prospective Diabetes Study (UKPDS), stimulation of insulin by sulfonylureas was not associated with increased cardiovascular events ([@B13]).

The concept of using dietary manipulations to treat type 2 diabetes, based on our knowledge of the contribution of gastric emptying and gut peptides to postprandial glycemic responses, appears to hold much promise.
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